問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Linkou Chang Gung Medical Foundation
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2015-03-01 - 2019-06-30
Condition/Disease
Chronic Hepatitis C
Test Drug
MK-5172A
Participate Sites10Sites
Terminated7Sites
Study ended1Sites
未分科
Digestive System Department
2015-04-01 - 2023-12-31
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Pembrolizumab (MK-3475)
Participate Sites6Sites
Terminated5Sites
Division of Hematology & Oncology
2015-04-01 - 2020-12-31
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Participate Sites4Sites
Terminated4Sites
2015-12-14 - 2020-10-31
Colorectal Carcinoma
Participate Sites5Sites
2016-05-01 - 2020-04-30
Advanced Hepatocellular Carcinoma
Pembrolizumab (MK-3475) /KEYTRUDA
Participate Sites7Sites
Terminated6Sites
2015-12-01 - 2026-12-31
Advanced Solid Tumors
Participate Sites8Sites
Recruiting8Sites
2013-08-01 - 2015-12-31
2013-09-01 - 2018-06-30
Participate Sites1Sites
Terminated1Sites
2013-03-01 - 2020-12-10
2012-08-01 - 2016-12-31
全部
